Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
Sponsor: Vanda Pharmaceuticals
Summary
The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one weight-related condition. The study is placebo-controlled with two treatment arms.
Official title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Tradipitant on Nausea and Vomiting After GLP-1R Agonist Administration in Healthy Overweight or Obese Volunteers
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
280
Start Date
2026-02-25
Completion Date
2026-12-01
Last Updated
2026-03-03
Healthy Volunteers
Yes
Conditions
Interventions
Tradipitant
Oral Capsule
Placebo
Oral Capsule
Locations (2)
Vanda Investigational Site
Los Angeles, California, United States
Vanda Investigational Site
New York, New York, United States